Rocket Pharmaceuticals, Inc. RCKT 深 滬
交易中 09-17 11:39:04 美东时间
3.625
+0.145
+4.17%
華盛通- 最 高3.755
- 今 開3.59
- 成交量 91.29万股
- 最 低 3.52
- 昨 收 3.48
- 總市值 3.98亿
- 52周最高 5.45
- 市盈率 靜 --
- 換手率 0.83%
- 52周最低 2.53
- 委 比 -32.01%
- 總股本 1.10亿
- 歷史最高 67.48
- 量 比 1.51
- 振 幅 6.75%
- 歷史最低 2.19
- 每 手 1
- 風險率 0.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 矿业股获齐声唱多！金田、纽曼矿业等目标价均获上调；携程遭看淡至60美元，较现价仍溢价5成
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从10.25美元升至11美元；Needham：上调Rocket Pharmaceuticals"买入"评级，目标价9美元
今天 16:16
Rocket Pharmaceuticals Aligned With FDA on Continued Enrollment and Dosing and key elements of Phase 2 trial of RP-A501 for Danon disease
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced alignment with the U.S. Food and Drug Administration (FDA) on cont...
09-15 19:12
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
Wedbush Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $15
Wedbush analyst Yun Zhong maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $16 to $15.
08-11 21:51
Rocket Pharmaceuticals Q2 Adj. EPS $(0.37) Misses $0.24 Estimate
Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $0.24 by 254.17 percent. This is a 40.32 percent increase over losses of $(0.62) per share from the same period last year.
08-11 04:21
Twist Bioscience Sees AI Drug Discovery Pipeline Expand
Twist Bioscience Corporation (NASDAQ:TWST) stock is up on Monday as the company reported its fiscal 2026 third-quarter financial results and raised fiscal 2026 guidance. The life science company reported an adjusted loss of 56 cents per share, missing the consensus loss of 50 cents. The sales came i...
08-04 00:13
Rocket Pharma Announces Clinical Safety Update Regarding Initial Three Patients Treated Under Modified Protocol For Global, Pivotal Phase 2 Trial Of RP-A501 In Danon Disease
Initial three patients were treated safely; RP-A501 was well-tolerated with no TMA or capillary leak syndrome observed Rocket is actively engaging with the FDA to align on the path to pivotal trial completion; regulatory pathway update expected in the second half of 2026 Comprehensive Danon disease ...
08-03 19:14
9 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers American Shared Hospital (AMEX:AMS) stock rose 14.2% to $1.61 during Wednesday's after-market session. The market value of their outstanding shares is at $9.7 million. Greenland Mines (NASDAQ:GRML) stock moved upwards by 7.18% to $0.24. The company's market cap stands at $34.7 million. Lunai...
06-25 05:05
Rocket Pharma updates cash position after selling priority review voucher
Rocket Pharmaceuticals (RCKT) on Friday disclosed more than $320M in cash, cash equivalents, and investments pro forma after completing the previously disclosed sale of its rare pediatric disease prio...
06-12 19:31
Rocket Pharmaceuticals Closes Sale Of Its Rare Pediatric Disease Priority Review Voucher For Gross Proceeds Of $180M
The Rare Pediatric Disease Priority Review Voucher was granted by the FDA in March 2026 in connection with the approval of KRESLADI™, Rocket's gene therapy for severe leukocyte adhesion deficiency-I (LAD-I), a rare and life-threatening primary immunodeficiency. As previously reported, before the PRV...
06-12 19:02
